ReviewJournal of affective disorders2017
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Review in Journal of affective disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.Molecular psychiatry · 2022Pooled it
- Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.Journal of affective disorders · 2025Trial
- Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.Trends in psychiatry and psychotherapy · 2025Trial
- Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.Journal of child and adolescent psychopharmacology · 2024Trial
- Ketamine's acute effects on negative brain states are mediated through distinct altered states of consciousness in humans.Nature communications · 2023Trial
- Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Effect of low-dose esketamine combined with labor analgesia on postpartum depressive symptoms following spontaneous labor: a randomized controlled trial.Frontiers in medicine · 2026Article
- Sympathetic activation but not dissociation linked to ketamine's sustained antidepressant effect.Therapeutic advances in psychopharmacology · 2026Article
- Overlap and Divergence in Ketamine and Lithium Response in Bipolar Disorder: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Case Report: A possible association between significant dissociations after esketamine treatment and histrionic personality disorder.Frontiers in psychiatry · 2025Article
- Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study.Translational psychiatry · 2024Article
- Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.Psychopharmacology · 2024Article
- Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression.Therapeutic advances in psychopharmacology · 2024Article
- Randomized trial of ketamine masked by surgical anesthesia in patients with depression.Nature. Mental health · 2023Article
- Suicidal ideation and suicide attempt following ketamine prescription in patients with treatment-resistant depression: a nation-wide cohort study.Research square · 2023Article
- Pharmacological Treatment of Bipolar Depression: A Review of Observational Studies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.Psychopharmacology · 2021Article
- Can Intraoperative Low-DoseFrontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAntidepressant response to a single subanesthetic dose infusion of the glutamatergic modulator ketamine is transient in most depressed patients; however, a minority continue to experience an extended response. This study examined depressive symptoms and potential clinical predictors of extended response to ketamine in subjects with mood disorders.
methodsSubjects were diagnosed with either major depressive disorder (MDD) or bipolar depression. All subjects were treatment-resistant and experiencing a major depressive episode of at least moderate severity. MDD subjects were unmedicated and those with bipolar depression were receiving therapeutic-dose lithium or valproate. All subjects received a single 0.5mg/kg ketamine infusion. Data were collected pre-infusion (baseline) and at days one, 14, and 28 post-infusion.
resultsTwelve of 93 (12.9%) participants continued to meet response criteria (50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score) at two weeks. All depressive symptoms assessed by the MADRS were improved at two weeks in ketamine responders except for sleep duration/depth. A positive family history of alcohol use disorder in a first-degree relative (FHP) and greater dissociation during the infusion were associated with better antidepressant response at two weeks. Improved measures of apparent sadness, reported sadness, inability to feel, and difficulty concentrating at day 1 correlated most strongly with antidepressant effects at two weeks. LIMITATIONS: Post-hoc design, small sample size, diagnostic heterogeneity.
conclusionsStatic (FHP) and dynamic (improved depressive symptoms) factors may be clinically useful in predicting whether a patient will have an extended response to ketamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.